

Index

A

- AAT. *See* α 1-antitrypsin deficiency
- 4-ABP. *See* 4-aminobiphenyl
- Accord (smoking system), 18
- ACE. *See* Angiotensin-converting enzyme inhibitors
- Acetaldehyde
- in animal studies, 181
 - health effects, 29, 49, 298
 - in tobacco smoke, 112, 229*t*
- Acrolein
- DNA adducts, 272
 - in Eclipse, 18
 - health effects, 29, 59, 72, 365, 439*t*
- Activated charcoal filters, 39, 46–47
- Acute tolerance, 116
- Adaptive immunity, 450*f*, 454*f*
- Addiction. *See* Nicotine addiction
- Additives, 34, 44–45
- required reporting of, 20
- Adhesion molecules, 371, 378
- Adolescents
- chronic tolerance, 117
 - epidemiology of smoking among, 156
 - nicotine dependence measurement in, 156–161
 - reinforcement, 118
 - sensitivity to nicotine addiction, 117
- Adults
- hematocrit levels, 377
 - prevalence of smoking and nicotine dependence, 162–167
 - psychiatric comorbidity, 167–169
- Advance cigarettes, 17
- Advertising
- impact of, 654
 - lower yield tobacco products, 19
 - recommendations, 662, 663, 664
 - regulation, 653
- Aerosols, particle-size distribution in, 50
- Affective dimensions of smoking recovery, 173–174
- Affective symptoms of tobacco withdrawal, 175–176
- A549 cell line, 60
- African Americans
- adolescents, 156, 181
 - GSTP1 gene, 249
 - heart disease, 361
 - mortality, 361
 - smoking behavior, 48, 159
 - smoking topography, 48, 137
- AGT. *See* *O*⁶-alkylguanine-DNA alkyltransferase
- Airway epithelial cells, 288–290
- Airway obstruction, 444, 445*f*
- Airway remodeling, 453–456
- AKT. *See* Protein kinase B
- Alaska Natives, 156, 162
- Albany Study, 361
- Alcohol abuse
- baclofen and, 129
 - carcinogenesis and, 298
 - reinforcement and, 120, 121
 - smoking cessation and, 169, 174
- Aldehydes, 38–40
- Alkylating agents, products of, 234
- Allergic reactions to nicotine, 74
- All-trans retinoic acid, 491
- α 1-antitrypsin (AAT)
- deficiency, 70, 445, 449*f*, 475–476
- α -tocopherol, 461
- Alveolar macrophages, 300, 440*f*, 451, 462
- American Academy of Family Physicians, 661
- American Academy of Pediatrics, 661
- American College of Physicians, 661
- American Correctional Association, 660
- American Indians, smoking prevalence among, 156, 162
- American Medical Association, 661
- American Nursing Association, 661
- Amino acid deficiencies, 600
- 4-aminobiphenyl (4-ABP), 42*f*, 227
- adducts, 243*f*
- in bladder cancer, 299*t*
 - chemical structure, 231*f*
 - in mainstream smoke, 228*t*
 - metabolism, 236*f*
- 4-aminobiphenyl-C8-deoxyguanosine, 271*t*, 273
- Angiogenesis, 453–454
- Angiotensin-converting enzyme (ACE) inhibitors, 360
- Anhedonia, 131
- Animal studies
- cardiovascular and cerebrovascular, 67–69
 - cytotoxicity, 61–62
 - emphysema, 466–467, 491–492
 - fertility, 71–72
 - inhalation, 63–67
 - oxidative stress, 465
 - reproductive and developmental, 71–74
 - respiratory, 69–71
 - skin-painting, 62–63

Note: *t* following a number refers to a Table; *f* following a number refers to a Figure.

Antidepressant drugs, 134–135
Antioxidants, 379. *See also specific substance*
 levels in smokers, 373
 in lungs, 459–461
Antiprotease-protease imbalance, 472
 evidence summary, 495
Antiprotease therapy, 493
Antipsychotic drugs, 134–135
Anxiety disorders, nicotine dependence and, 160, 168
Anxiolytic effects, 126
Aortic aneurysm, 362
Apolipoprotein level, 388
Apoptosis, 284, 493–494
Apurinic/apurimidinic sites, 273
Aromatic amines, 41–42, 227
 as biomarkers, 230–232
 bladder cancer and, 241, 250
 in mainstream smoke, 228*f*
Arsenic, 229*f*
Asbestos, 298
 in cigarette filters, 16
Asian Americans
 cardiovascular disease in, 361
 PI *Z alleles, 475
 smoking prevalence, 156, 162
Aspirin, 375, 380
Associative learning processes, 120–121, 181
Asthma, 439*t*
Atherosclerosis, 362, 363, 365
Atorvastatin, 380
Attitudinal influences, 172, 176–177

B

Baclofen, 128, 129
BAL. *See* Bronchoalveolar lavage
Base excision repair, 253–254, 255*f*, 262*t*
 polymorphisms in, 264–265
Bayley Scales of Infant Development, 541
B cells, 452*f*, 453
BCL-2 family proteins, 284, 285
Benzene
 as biomarker, 233, 234
 in cigarette smoke, 227
 metabolic activation, 237
Benzo[*a*]pyrene
 DNA adducts, 243*t*
 in mainstream smoke, 228*f*
Benzo[*a*]pyrene-7,8-diol-9,10-epoxide-N2-deoxyguanine
 stereoisomers, 273
Beryllium, 229*f*
β-adrenergic receptors, 289

Beta-carotene, 461
Bidis, 361
Biomarkers. *See also specific biomarkers*
 of addiction potential, 655, 656*t*
 of biologically effective dose, 53–54
 breath and blood, 234
 cardiovascular, 391–394
 conclusions, 9–10, 79
 of exposure, 52–53, 78
 general concepts, 51–52
 of inflammation, 392*t*–393*t*, 402, 463, 471
 of potential harm, 54–56, 78
 of protease involvement in emphysema, 491
 urinary, 230–234
Birth defects, 539–540, 542*t*–548*t*, 601, 602*t*–603*t*
Birth weight. *See* Low birth weight
Black tobacco, 55
Bladder cancer, 307, 324
 aromatic amines and, 241, 250
 black tobacco smokers and, 55
 gene mutations, 282*f*, 283
 gene promoter hypermethylation, 294
 risk factors, 54–55, 250, 268
Blonde tobacco, 55
Blood
 alterations in, 375–380 (*See also* Thrombogenic effects)
 biomarkers, 234
 DNA adducts in, 244–245
 hyperviscosity, 585
Blood flow, 576–577
Blood pressure, 368
 maternal, 575
Blood vessels, alterations in, 380–381
Body weight. *See also* Low birth weight
 smoking and, 77, 129
Boston Early-Onset COPD Study, 477, 478*t*, 479
Breast cancer, 525, 606
Breath biomarkers, 234
British Doctors' Study, 648
Bronchitis, chronic, 439*t*, 441–443, 477
Bronchoalveolar lavage (BAL), 516
Brundtland, Gro Harlem, 654
Bupropion, 134, 135, 154, 397*t*, 400–401
Bureau of Alcohol, Tobacco, Firearms and Explosives, 663
Buspirone, 135
1,3-butadiene
 animal studies, 67, 297
 biomarker of exposure, 52
 cancer risk, 29
 in lung cancer, 299*t*
 metabolic activation, 235, 237, 238
 in tobacco smoke, 79, 227, 229*t*

C

- Cachexia, 474
- Cadmium
 as biomarker, 234
 placental levels of, 55
 pulmonary injury and, 439*t*
 reproductive and developmental effects, 568, 583, 587, 588
 in tobacco smoke, 40–41, 227, 229*t*, 365
- California Birth Defects Monitoring Program, 601
- Cambridge glass fiber filters, 30, 31
- Cancer, 224–226. *See also* Carcinogens; *specific types of cancer*
 cell-cycle control in, 294–296
 cell-surface receptors, activation of, 288–292
 conclusions, 10, 304
 evidence summary, 302–303
 gene mutations, 274–278
 gene promoter hypermethylation, 292–294
 pathway of causation, 226*f*
 research recommendations, 657
 risk reduction, 664–666
 signal transduction, 284–288
- Cancer Prevention Study II, 355–356
- Candidate gene studies, 141–145, 182, 262*t*, 480*t*–486*t*
- Carbon dioxide, 30, 31
- Carbon filters, 60
- Carbon monoxide (CO)
 as biomarker, 392*t*
 cardiovascular disease, 392*t*
 in novel tobacco products, 18
 in oxidative stress, 463*t*, 471
 reproductive and developmental effects, 584–586
- Carbonyl compounds, 39
- Carboxyhemoglobin, 364*f*, 492
 maternal, 585
- Carcinogens, 227–230. *See also* DNA adducts; *specific carcinogens*
 biomarkers, 230–235
 enzymology, 237–241
 gene polymorphisms, 245–251
 metabolic activation and detoxification, 235–237
 specific cancers caused by, 298–300
TP53 mutations and, 278–283
 whole smoke and condensate, 296–297
- Carcinogenesis, synergistic interactions in, 297–298
- Carcinogen-metabolizing genes, 245–251
- Cardiomegaly, 69
- Cardiovascular disease and effects, 6*f*. *See also* Endothelium; Hemodynamic effects; Inflammation; Thrombogenic effects; *specific diseases*
 African Americans, 361
 animal studies, 67–69
 biomarkers, 391–394
 conclusions, 10–11, 408
 in diabetics, 383
 evidence summary, 407
 harm reduction, 402–407
 implications, 407
 lower yield tobacco products and, 362
 malformations, 540, 546*t*–547*t*
 mechanisms, 366*f*, 367
 mortality, 356–357, 359, 361, 362
 nicotine replacement therapy and, 368, 369
 pathophysiology, 363–367
 risk assessment, 355–356
 secondhand smoke and, 363
 smoking cessation and, 394–402
 sudden death from, 361
 2006 Surgeon General's report on, 355, 363
- Carlton cigarettes, 50–51
- Casing, tobacco, 44
- Catalase, 460
- Catecholamines, 76–77
- Causal agents, classification of, 7–8
- Causal relationships
 criteria, 5, 7*t*
 inference of, 3*t*
- CCND1* gene, 294–295
- CDC. *See* Centers for Disease Control and Prevention
- CD4 helper T cells, 453
- CDKN2A (P16)* tumor-suppressor gene, 292, 680*t*
- Cell-cycle control, 294–296
- Cell-derived oxidants, 462
- Cellulose-acetate filters, 36
- Centers for Disease Control and Prevention (CDC)
 lung cancer and COPD study, 437
- Centilobular emphysema, 446–447, 448*f*
- Cerebrovascular disease, 357*f*, 361
 mortality, 361
- Cervical cancer, 4*f*, 225, 300, 324
- Cervical mucus biomarkers, 53
- Characterized adducts, 242–244
- CHD. *See* Coronary heart disease
- Chemistry of tobacco smoke. *See also specific constituents*
 additives, 44–45
 aromatic amines, 41–42
 cardiovascular disease and, 363–367
 conclusions, 9–10, 79
 delivery of chemicals, 45–51
 heavy metals, 40–41
 heterocyclic amines, 43–44
 nicotine and free nicotine, 32–34
 N-nitrosamines, 34–37
 phases of tobacco smoke, 30–31
 polycyclic aromatic hydrocarbons, 37–38
 volatile and aldehyde compounds, 38–40
- Chewing gum. *See* Nicotine gum
- Children
 active smoking, effects of, 438*t*
 secondhand smoke exposure, effects of, 4*f*, 438*t*
 of smokers, 57–58
- Chlorisondamine, 132
- Cholesterol, low-density lipoprotein (LDL), 379–380. *See also* Lipid abnormalities

- CHRNA4* gene, 141, 144*t*, 145*t*, 182, 680*t*
CHRNA7 gene, 141, 144*t*, 680*t*
Chromium, 229*t*, 589
Chromosome instability and loss, 274–278
Chronic bronchitis, 439*t*, 441–443, 477
Chronic disease, 4*f*
Chronic obstructive pulmonary disease (COPD)
 apoptosis, 473
 evidence summary, 494–495
 genetic associations, 476–486
 hypersecretion of mucus, 472
 lung inflammation, 472–473
 oxidative stress in, 471–474
 pathogenesis, 471–472
 phenotypes, 476–479
 protease-antiprotease imbalance, 472
 pulmonary hypertension and, 447
 severity classifications, 443–444
 1984 Surgeon General's report on, 437
 systemic involvement, 473–474
Chronic tolerance, 116–117
Cigarettes. *See also specific types or brands of cigarette*
 defined, 15
 smoked per day, 356–357
Cigarette design
 conclusions, 9, 21
 history, 15–17
 lower yield tobacco products, 18
 novel cigarette products, 17, 18–19
 product evaluation, 19
Cigarette filters. *See* Filters
Cigarette-like products. *See* Novel tobacco products
Cigarette paper, 15
Cigarette smoke. *See* Tobacco smoke
Cigarette substitutes. *See* Novel tobacco products
Cigars, 362, 363
Ciliotoxicity assays, 59
Circulating proteins, 378–379
Cleft lip and palate, 11, 538–540, 582, 601
 genotype and, 602*t*–603*t*
 maternal smoking and, 542*t*–545*t*
Clinical imaging studies, 134
Clonidine, 401, 607
Cloud motion, 51
Clozapine, 136
Clubfoot, 540, 577
CO. *See* Carbon monoxide
Cobalt, 41
Cocaine, 105
Cochrane Database of Systematic Reviews, 395
Cognitive domain, impact on, 554
Coherence, 5–7
Collagenase, overexpression of, 493
Comet assay, 263–264
Committee to Assess the Science Base for Tobacco Harm
 Reduction, 651
Compensatory smoking, 111, 403
Composite International Diagnostic Interview-Substance Abuse
 Module, 162
Conclusions
 biomarkers, 9–10, 79
 cancer, 10, 304
 cardiovascular disease, 10–11, 408
 cigarette design, 9, 21
 mechanisms of disease production, 9
 nicotine addiction, 10, 183
 pulmonary diseases, 11, 496
 reproductive and developmental effects, 11, 612
 respiratory and pulmonary disease, 11, 496
 secondhand smoke exposure, effects of, 9
 smoking cessation, 11, 408
 tobacco smoke chemistry and toxicology, 9–10, 79
Conditioned stimuli, 120–121
Conditioning, 120–124
Congenital lobar emphysema, 447
Consumer perception, 19, 662
COPD. *See* Chronic obstructive pulmonary disease
Copenhagen City Heart Study, 443
Coronary blood flow, 368–370
Coronary heart disease (CHD)
 cigarettes smoked per day, 356–359
 duration of smoking and, 359
 men, 357*f*
 mortality, 360*t*
 race and ethnicity, 361
 secondhand smoke exposure and, 647
 smoking cessation, 359–360
 women, 360
Cotinine, 112
 as biomarker, 52
 chemical structure, 32*f*
Counseling, smoking cessation, 396*t*, 398–399, 606–607
COX-1. *See* Cyclooxygenase-1
COX-2. *See* Cyclooxygenase-2
Craniosynostosis, 540, 548*t*–554*t*
Craving, 123–124, 158, 175*f*
C-reactive protein, 379
CREB. *See* Cyclic adenosine monophosphate-response element
 binding protein
Cresols, 29
Cross-complementation group 1 for excision repair (*XRCCI*)
 gene, 264–265, 266
Cryptorchidism, 548*t*–553*t*
Cue-provoked craving, 123–124
Curing process, 35, 78
Cyanide, 31
Cyclic adenosine monophosphate-response element binding
 protein (CREB), 134
Cyclooxygenase-1 (COX-1), 288
Cyclooxygenase-2 (COX-2), 288, 289
CYP1A1 gene, 246–247, 248–249
CYP2A6 gene, 141, 142*t*
CYP2A13 gene, 247
CYP2B6 gene, 154

CYP2E1 gene, 142*t*, 247
Cytochrome P-450 enzymes, 237–238
Cytogenic effects, 57, 58–59
Cytoplasmic kinase, activation of, 290–291
Cytotoxicity, 59–61
 animal studies, 61–77
 cardiovascular and cerebrovascular system, 67–69
 endocrine system, 76–77
 immune system, 74–76
 reproductive and developmental systems, 71–74
 respiratory system, 63–67, 69–71

D

Death. *See* Mortality
Decision-tree analyses, 173
Demographic variables, 172–173
Denicotinized tobacco, 50, 123, 129
Department of Health and Human Services, 661, 663
Depression, nicotine dependence and, 135, 173–174
Dermal application of cigarette smoke condensate, 62–63
Desmosine, 491
Developmental effects. *See* Reproductive and developmental effects
Developmental immunotoxicity, 597–598
Diabetes
 cardiovascular disease and, 383
 insulin resistance, 384–385
 macrovascular complications, 386–387
 metabolic control, 384
 microvascular complications, 385–386
 mortality, 386
 pathophysiological mechanisms, 387
 peripheral arterial disease and, 382
 risk for, 383–384
Diabetes Control and Complications Trial, 386
Diagnostic and Statistical Manual, Third Edition Revised (DSM-III-R), 162, 165
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), 106, 109*t*
Disease. *See also specific diseases*
 causation schema, 5*f*
 mechanisms of (*See* Mechanisms of disease production)
 smoking causally linked to, 4*f*
Distal acinar emphysema, 447
Distress tolerance, 174
DNA adducts, 236*f*, 244–245
 characterized, 242–244
 conversion to mutations, 268–273
 genotoxicity assessment, 273
 protein adducts as surrogates for, 245
 repair, 252–259
 uncharacterized, 244
DNA damage, 57. *See also* Chromosome instability and loss

DNA repair
 adducts, 252–259
 base excision repair, 253–254, 255*f*, 262*t*, 264–265
 comet assay, 263–264
 double-strand break repair, 259, 268
 8-oxoguanine DNA glycosylase activity assay, 263
 functional assays, 261–263
 genotype-phenotype correlations, 267–268
 mismatch repair, 258–259
 molecular epidemiology of, 259–268
 mutagen sensitivity assays, 263
 nucleotide excision repair, 254–257, 262*t*, 266–267
 *O*⁶-alkylguanine-DNA alkyltransferase, 252, 264
 OGG1 gene, 265
 transcription-coupled repair, 257–258
Dopamine
 candidate gene studies, 146*t*–149*t*
 neural pathways, 127*f*
 neurotransmitter and receptor systems, 141–144
 nicotinic acetylcholine receptors, 126
Dopamine receptor D2 (DRD2), 141
Double-strand break repair, 259
 DNA repair, 259, 268
Down syndrome, 546*t*–551*t*
DRD2. *See* Dopamine receptor D2
Drug dependence, 106–108
 1988 Surgeon General's report on, 106
DSM-III-R. *See* *Diagnostic and Statistical Manual, Third Edition Revised*
DSM-IV. *See* *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*
Dual product use, 19
Dye exclusion assay, 60

E

Eclipse smoking system, 18, 19
Ectopic pregnancy, 531–534, 609
 2004 Surgeon General's report on, 531, 609
Educational status, smoking cessation and, 173
“Effective pH,” 33
EGFR gene, 276–277, 289–290, 442
8-oxoguanine DNA glycosylase activity assay, 263
Elastases, 482–483, 488–489
“Elastic” cigarettes, 49–50
Elastin-derived peptides, 401
Electronic Nicotine Delivery Systems, 17–18, 31*t*, 32
ELF. *See* Epithelial lining fluid
Emergent processes, 174–178, 179
Emphysema, 445–446, 449*f*
 animal studies, 466–467, 491–492
 antiprotease therapy, 493
 centilobular, 446–447, 448*f*
 distal acinar, 447

- mantle, 447
 - matrix metalloproteinases, 489t
 - panacinar, 446–447
 - paraseptal, 447
 - pathogenesis of, 472, 487–494
 - protease-antiprotease imbalance, 495
 - protease involvement, biomarkers of, 491
 - unilateral, 447
- Ending the Tobacco Problem: A Blueprint for the Nation*, 652, 660–664
- Endocannabinoid system, 129–130, 132
- Endocrine system, 76–77, 555–565
- men, 557–561, 562–564
 - pregnancy, 557
 - premenopause, 555–557
 - women, 555–557, 558t–560t
- Endothelial progenitor cells, 370
- Endothelium
- dysfunction, 370, 371
 - nitric oxide and, 371–372
 - pathologic angiogenesis, 373–374
 - regeneration of, 370–371
 - vasodilation, 372–373
- Endothelium-dependent vasodilation, 372–373
- ENDS. *See* Electronic Nicotine Delivery Systems
- Environmental context of learning and conditioning, 122–124
- Environmental Protection Agency (EPA), 7
- Environmental tobacco smoke exposure. *See* Secondhand smoke exposure
- Enzyme antioxidants, 459–461. *See also specific substances*
- Enzymology of carcinogen metabolism, 237–245
- EPA. *See* Environmental Protection Agency
- Epidermal growth factor receptor, 287
- Epithelial injury, 465, 470
- Epithelial lining fluid (ELF), 438
- Epoxide hydrolases, 238–239
- ERBB receptors, 289
- ERK. *See* Extracellular signal-regulated kinases
- Esophageal cancer, 4f, 297, 298
- Estriol, birth weight and, 557
- Ethnicity, 361. *See also specific ethnic groups*
- Ethylene oxide, 227, 229t, 240
- Eugenol, 44
- Euglycemic hyperinsulinemic clamp technique, 384
- European Americans
- AAT deficiency, 475
 - candidate gene studies, 142t–144t
 - cigarette brands, popular, 49
 - smoking topography, 48
- Evidence
- description of, 8
 - evaluation of, 3t, 5–7
- Evidence summaries
- cancer, 302–303
 - cardiovascular disease, 407
 - COPD, 494–495
 - genetics, 302–303
 - genetic susceptibility to tobacco smoke, 495
 - harm reduction, 407
 - nicotine addiction, 180–182
 - oxidative stress, 463–465, 494–495
 - protease-antiprotease imbalance, 495
 - reproductive and developmental effects, 577–583, 608–611
- Exhaled air biomarkers, 467
- Exocyclic etheno adducts, 273
- Expanded tobacco, 45, 62, 78
- Exposure reduction, 402–406
- Extracellular signal-regulated kinases (ERK), 291

F

- Fagerström Test for Nicotine Dependence (FTND), 107t, 109t, 163t
- Fagerström Tolerance Questionnaire (FTQ), 106, 107t, 109t
- Family Smoking Prevention and Tobacco Control Act* (2009), 8, 20, 653, 680
- FDA. *See* Food and Drug Administration
- Federal Cigarette Labeling and Advertising Act* (1965), 653
- Federal Trade Commission (FTC), 16, 29
- Fertility. *See also* Reproductive and developmental effects
- animal studies, 71–72
 - female, 525–526
 - male, 526–527
 - maternal smoking and, 526
 - subfertility, 525–526
 - 2001 Surgeon General's report on, 526
- Fetal effects. *See also* Low birth weight
- animal studies, 72–73
 - birth defects, 539–540, 542t–548t, 601, 602t–603t
 - blood flow, 576–577
 - carbon monoxide and, 584
 - cardiovascular, 569t–570t, 570–574, 575
 - organogenesis, 577–583
 - pathophysiological mechanisms, 659–660
 - size and growth, 538
 - timing and critical periods, 577
- Fibrinogen, 379
- Filters (cigarette), 46–47
- activated charcoal, 46–47
 - asbestos in, 16
 - cellulose-acetate, 36
 - glass fiber, 30, 31
 - health risks, 16–17
- Filter ventilation holes, blockage of, 16, 49
- “599 list,” 44
- Flavorings, 44–45
- Flow-mediated arterial vasodilation, 391
- Fluoxetine, 135
- Fluvastatin, 380
- Folate levels in smokers, 58
- Food and Drug Administration (FDA), 8, 20, 653
- Food intake, smoking abstinence and, 129
- Formaldehyde, 227, 439t
- Framework Convention on Tobacco Control, 654

Framingham Heart Study, 139–140*t*, 361, 478
Free fatty acids, 384
 metabolism, 389–390
Free nicotine, 31–34
Free radicals, 457
FTC. *See* Federal Trade Commission
FTND. *See* Fagerström Test for Nicotine Dependence
FTQ. *See* Fagerström Tolerance Questionnaire
Functional assays, 261–263
Functional magnetic resonance imaging, 134
Future vision
 global tobacco epidemic, 647–651, 652–654
 recommendations, 655–666
 reducing risk from smoking, 671–672

G

γ -aminobutyric acid (GABA), 127*f*
 γ -glutamyltranspeptidase, 461
Gas phase of tobacco smoke, 4, 31, 462
 defined, 30
Gastroschisis, 540, 552*t*–553*t*
Gefitinib, 277
Gender factors. *See* Men; Women
Gene mutations, 268–273. *See also specific genes*
 chromosome instability and loss, 274–278
Gene profiling, 491
Gene promoter hypermethylation, 292–294
Gene silencing, 293
Genetics
 evidence summary, 302
 genetic susceptibility to tobacco smoke, 495
 lung cancer, 274, 275–278, 292–293, 307
 pharmacogenetics, 145–154
 of smoking behavior, 10, 137–145
 summary and future directions, 155
Genetic polymorphisms. *See also specific genes*
 in base excision repair, 264–265
 in double-strand break repair, 268
 epidemiology, 245–251
 maternal and neonatal, 600–605
 in nucleotide excision repair, 266–267
 in *O*⁶-alkylguanine-DNA alkyltransferase, 264
Genetic symbols, definitions and alternative nomenclature for, 679–688
Genotoxicity
 cigarette smoke condensate, 56–59
 DNA adduct assessment, 273
Genotype-phenotype correlations, 267–268
Glass fiber filters, 30, 31
Global genomic nucleotide excision repair, 254–257, 258
Global Initiative for Chronic Obstructive Lung Disease (GOLD), 443
Global tobacco epidemic, 647–651, 652–654
Glucose levels, 76

Glutamate, 126–128
Glutathione-S-transferases (GSTs), 239–240
Glutathione (GSH) system, 460–461
Glycosylases, 253–254, 263, 277*t*
GOLD. *See* Global Initiative for Chronic Obstructive Lung Disease
Growth control, loss of mechanisms for, 284–296
GSH. *See* Glutathione system
GSTM1 gene, 248–249, 482*t*
GSTP1 gene, 249
GSTP1 gene, 482*t*
GSTs. *See* Glutathione-S-transferases
GSTT1 gene, 249, 601, 605
G→T transversions, 278*f*, 279–283
Guidelines for Carcinogen Risk Assessment, 7
Gum. *See* Nicotine gum

H

Harm reduction, 402
 evidence summary, 407
 nicotine replacement therapy, 406
 reduced smoking, 403–406
Head cancers, 294
Health Professionals Follow-Up Study, 383
Heart disease. *See* Cardiovascular disease; Coronary heart disease
Heart rate, 368
 fetal, 569*t*–570*t*, 570–574, 575
 maternal, 568–570, 574–575
Heavy metals, 40–41
Hematocrit level, 377
Hemodynamic effects, 368–370
Heritability. *See* Genetics
HER-2/NEU gene, 276–277, 289
Heterocyclic amine protein pyrolysate products, 56
Heterocyclic amines, 43–44
Heterocyclic aromatic amines, 227
Hispanic Americans, 156, 361, 648
Homologous DNA recombination, 259, 260*f*
Honolulu Heart Program, 361
Hooked on Nicotine Checklist, 110*t*, 156
1-HOP. *See* 1-hydroxypyrene
Hormones
 maternal smoking and, 612
 men, 557–561
Host-cell reactivation assay, 261
HPRT. *See* Hypoxanthine phosphoribosyl transferase mutations
5HTT gene, 679
smoking status and, 151*t*
Hydrogen cyanide, 31, 439*t*
1-hydroxypyrene (1-HOP), 230, 231*f*, 391
Hypercholesterolemia, 370
Hypercoagulable state, 382
Hypersecretion of mucus, 472

Hypospadias, 540, 548*t*–553*t*
Hypoxanthine phosphoribosyl transferase (HPRT) mutations, 57
Hypoxia, 585

I

IARC. *See* International Agency for Research on Cancer
ICD-10. *See* *International Classification of Diseases, 10th Revision*
Ilomastat, 493
Imaging studies, 134
Immune system response, 74–76, 300
 of the lung, 450*f*, 451–453
 reproductive system and, 583–584
Implications
 cardiovascular disease, 407
 pulmonary diseases, 496
 reproductive and developmental effects, 606–608
“Incentive amplification,” 121
Income level, smoking prevalence and, 162
Inductive plethysmography, 50
Infant mortality, 538–539, 607
Inflammation, 382, 456
 biomarkers, 392*t*–393*t*, 463, 471
 lung, 472–473
Inhalation patterns, 50
Inhalation studies, 63–67
Inhalers, nicotine, 113*t*
Innate immunity, 450*f*, 454*f*
Institute of Medicine (IOM)
 biomarker definition, 52
 cigarette substitutes, 19, 651
 Ending the Tobacco Problem: A Blueprint for the Nation, 660–664
Insulin dosage, 384
Insulin resistance
 diabetes and, 384–385
 lipolysis inhibitors, 390
Insulin Resistance Atherosclerosis Study, 383
Intellectual abilities, prenatal exposure and, 541
INTERHEART study, 361, 367
International Agency for Research on Cancer (IARC), 7, 227, 228*t*–229*t*
International Classification of Diseases, 10th Revision (ICD-10), 106*t*
International Collaborative Study on Genetic Susceptibility to Environmental Carcinogens, 247, 249
International Organization for Standardization, 29
Intrauterine growth restriction (IUGR), 597, 604*t*–605*t*
Intrauterine growth retardation, 597, 604*t*–605*t*
In vitro studies
 AGT, 252
 oxidative stress, 463–465
In vivo studies, AGT, 252

IOM. *See* Institute of Medicine
Isoprostanes, 377
IUGR. *See* Intrauterine growth restriction

J

Jenkins Act, 663
Joint Commission on the Accreditation of Healthcare Organizations (JCAHO), 660

K

Kenacid blue binding assay, 60
Ketones, 39
Koch's postulates, 7
KRAS gene, 59, 277

L

Lactate dehydrogenase release assay, 60
Laryngeal cancer, 225, 283, 296, 299*t*
LBW. *See* Low birth weight
LDL. *See* Low-density lipoprotein
Lead, 40–41, 229*t*
 reproductive and developmental effects, 588
Learning and conditioning
 associative learning, 121
 environmental context, 122–124
 negative reinforcement, 122
 positive reinforcement, 121–122
 secondary reinforcement, 120–121
Legacy Tobacco Documents Library, 16
Legislation, tobacco control, 8
Leukemia, 4*f*, 299*t*, 300
Leukocytes, 451
Lifestyle
 healthy, promoting, 664–666
 as relapse risk factor, 172–173
“Light” tobacco products. *See* Lower yield tobacco products
Limb deficiency defects, 540, 577
Linkage studies
 COPD phenotypes, 477–479
 smoking behavior, 139*t*–140*t*, 140–141
Lipid abnormalities
 composition, 388
 epidemiology, 387–388
 free fatty acid metabolism, 389–390
 lipid transfer enzymes, 388
 oxidized lipoproteins, 388
 pathogenic mechanisms, therapeutic implications of, 390
 postprandial changes, 388–389

reverse cholesterol transport, 390
 smoking cessation, effects of, 390

Lipid peroxides, 467

Lipid transfer enzymes, 388

Lip occlusion of filter ventilation holes, 49

Lipolysis inhibitors, 390

Lipoproteins, 388

Lipoprotein-associated lipid transfer enzymes, 388

Liver cancer, 225, 299*t*

Low birth weight (LBW), 4*f*, 55
 cadmium exposure and, 588
 estriol and, 557
 maternal smoking and, 538, 539, 604*t*–605*t*
 polycyclic aromatic hydrocarbons and, 590*t*–592*t*, 597
 secondhand smoke exposure and, 538
 1964 Surgeon General's report on, 538
 2001 Surgeon General's report on, 538
 2004 Surgeon General's report on, 538

Low-density lipoprotein (LDL) cholesterol, 379–380

Lower yield tobacco products, 15, 18, 68, 73, 362
 cardiovascular disease and, 362
 consumer perception of, 19
 risk reduction with, 16, 17, 566

Lozenges, nicotine, 114, 395

Luciferase host-cell reactivation assay, 261–263

Lung cancer, 4*f*
 conclusions, 10
 family history and, 300–302
 genetics, 274, 275–278, 292–293 (*See also TP53 gene*)
 G→T transversions, 279–283
 mortality, 300
 1964 Surgeon General's report on, 5
 survival, 277–278

Lung Health Study, 403, 406

Lungs
 antioxidants in, 459–461
 characterized adducts in, 242–244
 defenses, 440*f*
 inflammation, 456, 472–473
 local oxidative stress, 467–469
 lymphoid collections, 452*f*
 tissue studies, 490–491
 uncharacterized adducts in, 244

Lymphoid collections in lung tissue, 452*f*

M

Macular degeneration, 374

Mainstream smoke, 30–31

Major depression, 135, 168

Mantle emphysema, 447

Marlboro cigarettes, 36, 49, 51

Maternal cardiovascular effects, 569*t*–570*t*, 571*t*–574*t*
 blood pressure, 575
 heart rate, 568–570, 574–575

Maternal smoking. *See also* Fetal effects; Reproductive and developmental effects
 hormones and, 612
 later fertility or fecundability, 526
 nicotine dependence in offspring, 160–161

Matrix metalloproteinases, 290, 489*t*

McCarthy Scales of Children's Abilities, 541

M cells, 452

McLeod syndrome (unilateral form of emphysema), 447

Mecamylamine, 111, 119, 373

Mechanisms of disease production, 3–5. *See also* Evidence
 conclusions, 9
 mechanisms of action, 7–8
 mode of action versus, 7
 schema for, 5*f*
 1964 Surgeon General's report on, 5

Memory, nicotine and, 126

Men
 coronary heart disease in, 357*f*
 endocrine system, 557–561, 562*t*–564*t*
 fertility, 526–527
 hormones, 557–561
 nicotine dependence prevalence in, 162
 nicotine reinforcement in, 120
 smoking cessation, 608
 smoking topography, 48

Menarche, 525

Menopause, 525

Menstrual cycle, 524–525, 608

Mentholated smoke, 66, 69

Mercury, 40, 41
 reproductive and developmental effects, 588, 589

Merit cigarettes, 50–51

Mesocorticolimbic brain system, 125–126

Mesolimbic dopamine system, 135–136

Metabolic activation of carcinogens, 235–237

Metals, 40–41, 229*t*. *See also specific metals*
 biomarkers, 234
 reproductive and developmental effects, 587–589

Methylcaconitine, 126, 130, 133

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 231*f*, 232

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
 chemical structure, 35*f*
 DNA adducts, 243*t*, 243*t*
 in mainstream smoke, 228*t*
 metabolism, 236*f*

Methylphenidate, 119

Micronutrient deficiencies, 599–600

Microsomal epoxide hydrolase, 486, 600

Minnesota Child Development Inventory, 541

Mismatch repair, 258–259

Modeling of smoking, 179

“Mode of action,” 7

Modified tobacco products. *See* Lower yield tobacco products;
 Novel tobacco products

“Molecular Koch's postulates,” 7

Molecular profiling, 649, 650f
Monitoring the Future study, 156
Monoamine oxidase, 457
Monocytes, 378
Mortality
 African Americans, 361
 cardiovascular disease, 356–357, 359, 361, 362
 cerebrovascular diseases, 361
 cigarettes smoked per day and, 356–357
 diabetes and, 386
 duration of smoking and, 359
 infant, 538–539, 607
 lung cancer, 300
 perinatal, 538–539
 PI *Z alleles and, 476
 preeclampsia and, 534
 smoking cessation and, 360, 394–395
 sudden death, 361
 women, 360
Motion Picture Association of America, 663
Motivation as relapse risk factor, 177–178
MPOWER framework (WHO), 653–654
MRPs. *See* Multidrug-resistance proteins
Mucin, 461
Mucociliary function, impaired, 69, 439f
Mucus hypersecretion, 472
Multidrug-resistance proteins (MRPs), 461
Multinational Study of Vascular Disease in Diabetes, 386
Multiple Risk Factor Intervention Trial Research Group, 360
Mutagen sensitivity assays, 263
Myeloperoxidase, 378
Myocardial infarction, 355, 366f
Myocardial ischemia, 366f, 367

N

NAB (*N'*-nitrosoanabasine), 34, 35f, 232
N-acetylcysteine, 467
N-acetyltransferases (NATs), 241
Nacystelyn, 467
Naloxone, 132
Naltrexone, 129, 155
Naphthalene, 598
Nasal cancer, 297, 299f
Nasal spray, nicotine, 113–114, 120, 124, 406
NATB. *See* *N'*-nitrosoanatabine
NAT2 gene, 246f, 249–250
National Cancer Institute, 661, 665
National Comorbidity Survey, 164–165, 168
National Emphysema Treatment Trial, 486
National Health Interview Survey, 162, 477
National Institute of Mental Health Diagnostic Interview Survey, 162
National Institutes of Health (NIH), 665
National Longitudinal Study of Adolescent Health, 161
National Mortality Followback Survey, 361

National Survey on Drug Use & Health, 157, 158, 162
NATs. *See* *N*-acetyltransferases
NDMA. *See* *N*-nitrosodimethylamine
“Necessary” causal agents, 7–8
Neck cancer, 294
Necrosis, 60–61
Negative reinforcement, 116, 118, 122, 124
“Neither necessary nor sufficient” causal agents, 8
Neonates, hematocrit in, 377
Nephropathy, 385–386
Neurochemical correlates of nicotine withdrawal, 132
Neurodevelopment, 540–554
Neuronal nicotinic receptors, 141, 144f
Neuropathy, 386
Neurosubstrates of nicotine dependence, 131–133
Neutral red incorporation assay, 60
Next cigarettes, 18
Niacin, 390
Nickel, 229f, 587
Nicotine
 allergic reactions to, 74
 bioavailability, 113
 chemistry of, 31–34
 delivery systems, comparison of, 114
 forms of, 33f
 free, 31–34
 metabolism, 141
 pharmacokinetics, 113–116
 reinforcement (*See* Nicotine reinforcement)
 reproductive and developmental effects, 586–587
 smokeless tobacco products and, 115f
 structure, 33f
 thrombosis and, 381–382
 tolerance, 116–117
 withdrawal (*See* Withdrawal)
Nicotine addiction. *See also* Relapse
 adolescent sensitivity to, 117
 clinical imaging studies, 134
 components of, 116–124
 conclusions, 10, 183
 definition, 105–108
 determinants of, 160–161
 evidence summary, 180–182
 genetics, 137–155
 measures of, 109f–110f
 pathophysiology of, 124–136
 physiological mechanisms and indicators, 116–124
 prevalence and trajectory toward dependence, 156–161
 research recommendations, 655–657
 summary of evidence, 180–182
 1988 Surgeon General's report on, 105–106, 180
Nicotine dependence
 adolescent, measuring, 156–161
 depression and, 135
 by dose, duration, and subpopulations, 165–167
 epidemiology of, 162–167
 men, 162
 neurosubstrates of, 131–133

- in offspring, maternal smoking and, 160–161
- prevalence, 156–167
- psychiatric comorbidity, 167–169
- schizophrenia and, 135–136
- summary and future directions, 135
- Nicotine gum, 111, 114*f*, 395
 - cardiovascular effects, 368, 369
 - craving cues and, 123–124
 - insulin resistance and, 384
 - nicotine bioavailability, 113*t*
 - safety, 406
 - for smoking cessation, 367
- Nicotine inhalers, 113*t*
- Nicotine lozenges, 114, 395
- Nicotine nasal spray, 113–114, 120, 124, 406
- Nicotine patches, 114*f*
 - addiction potential, 115
 - adolescents and, 158
 - cardiovascular risk, 367
 - cravings and, 123, 124
 - LH secretion, impact on, 587
 - nicotine bioavailability, 113*t*
 - for smoking cessation, 152–154, 389
 - weight gain and, 389
- Nicotine reinforcement
 - alcohol and, 119, 121
 - negative, 122
 - neurosubstrates of, 125–130
 - positive, 121–122
 - relapse and, 172
 - versus* smoking reinforcement, 120
- Nicotine replacement therapy (NRT), 145–154, 395
 - cardiovascular disease and, 381, 399–400, 406
 - cravings, reduction in, 124
 - gum (See Nicotine gum)
 - harm reduction, 406
 - lozenges, 114, 395
 - nasal spray, 113–114, 120, 124, 406
 - nicotine concentration and, 113
 - patch (See Nicotine patches)
 - pregnancy and, 607
 - recommendations, 663
 - smoking reduction and, 404*t*
- Nicotine tolerance, 116–117
- Nicotine withdrawal. *See* Withdrawal
- Nicotinic acetylcholine receptors, 125
- NIH. *See* National Institutes of Health
- Nitric oxide
 - as free radical, 457
 - generation, 375–377
 - oxidative stress, biomarker of, 463*t*
 - reproductive and developmental effects, 600
 - vascular effects, 371–372, 380, 585
- Nitriles, 40
- Nitrogen oxide, 39, 439*t*
- N*-nitrosamines, 34–37
 - as biomarkers, 232
 - carcinogenicity, 226, 227
- Nitrosamino acids, 232–233
- N*'-nitrosoanabasine (NAB), 34, 35*f*, 232
- N*'-nitrosoanatabine (NATB), 34, 232
- N*-nitrosodimethylamine (NDMA), 235, 236*f*
- N*'-nitrosornicotine (NNN), 34, 228*t*, 232
- NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol), 231*f*, 232
- NNK. *See* 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
- Nonenzymatic antioxidants, 461
- Nonhomologous end-joining of DNA, 259, 261*f*
- Non-neoplastic histopathologic changes, 71
- Non-small-cell lung cancer, 292–293
- Nonvolatile nitrosamines, 34
- Norepinephrine, 130, 132
- Normative Aging Study, 486
- Nornicotine, 111–112
- Nortriptyline
 - pregnancy and, 607
 - for smoking cessation, 135, 401, 402
- Novel tobacco products, 17, 18–19
 - conclusions, 9
- 1,*N*²-propanodeoxyguanosine, 272–273
- NRT. *See* Nicotine replacement therapy
- NRXN1* gene, 141
- NRXN3* gene, 141
- Nuclear coronary perfusion studies, 394
- Nuclear factor-kappa B, 287–288
- Nucleotide excision repair, 254–257, 262*t*, 266–267
- Nurses' Health Study, 360, 361, 383, 386
- Nutrient deficiencies, 599–600

O

- O*⁶-alkylguanine-DNA alkyltransferase (AGT)
 - DNA repair, 252, 264
 - in vitro studies, 252
- Obama, Barack, 8
- Office on Smoking and Health, 8
- OGG1* gene, 265
- Olefins, 40
- O*⁶-methyldeoxyguanosine, 272
- O*¹⁴-methylthymidine, 272
- Omni cigarettes, 17
- Oncogenes. *See also specific genes*
 - activation, 275–277
- Opioid system, 129–130, 132
- O*¹⁶-pyridyloxobutyl-deoxyguanosine, 272
- Oral cancer, 225, 282*f*, 323*t*
- Oral premalignant lesions, 58
- Organogenesis, 577–583
- Orofacial clefts. *See* Cleft lip and palate
- Oviduct (tubal) function, 72, 534, 566, 586
- Ovum (ova), 57
- Oxidants, 462
- Oxidative DNA damage, 54, 233
- Oxidative DNA repair lesions, 54

- Oxidative stress
 animal studies, 465–467
 assessment, 463
 consequences, 465–470
 in COPD, 471–474
 evidence, 463–465, 494–495
 human studies, 467
 inflammation, 465, 470, 472
 local, 467–469
 platelet function and, 377
 reactive oxygen species and, 457–459
 systemic involvement, 469–470
 in vitro studies, 463–465, 468*t*–469*t*
- Oxidized lipoproteins, 388
- Oxidized low-density lipoprotein cholesterol, 379–380
- Oxidizing chemicals, 391, 407
- 8-oxodeoxyguanosine, 233, 272
 chemical structure, 231*f*
 mutational specificity, 271*t*
- 8-oxoguanine DNA glycosylase activity assay, 263
- P**
-
- Pack-years, 267*n*
- PAD. *See* Peripheral arterial disease
- PAHs. *See* Polycyclic aromatic hydrocarbons
- Panacinar emphysema, 446–447
- Pancreatic cancer, 4*f*, 291, 298–300
- Pancreatic juice biomarkers, 53
- Paper, cigarette, 15
- Papillomas, 62
- Paracatricial emphysema, 447
- Paraseptal emphysema, 447
- Particulate (tar) phase of tobacco smoke, 30
 constituents in, 31, 35, 488
- Patch. *See* Nicotine patches
- Pathologic angiogenesis, 373–374
- Peabody Picture Vocabulary Test, 541
- Perinatal mortality, 538–539
- Peripheral arterial disease (PAD), 362
- Persistent innate and adaptive immune inflammatory response, 453, 454*f*
- Person risk factors for relapse, 172–174
- P53 protein, 285–286
- pH, effective, 33
- Pharmacogenetic approaches to nicotine addiction, 145–154
- Pharmacokinetics of nicotine, 113–116
- Pharmacotherapy for smoking cessation, 401–402. *See also* Nicotine replacement therapy; *specific drugs*
- Phenotypes
 COPD, 476–479
 defined, 108
 smoking behavior, 124, 139*t*–140*t*, 143*t*–145*t*, 146*t*–153*t*
- Philip Morris (tobacco manufacturer), 16, 17, 18, 36
- Phosphatidylinositol-3 kinase, 287
- Phosphatidylinositol 3'-phosphatase, 287
- PHS. *See* Public Health Service
- Physicians' Health Study, 380, 383
- Pioglitazone, 390
- Pipes, 362
- PI* Z alleles, 475, 476
- PKB. *See* Protein kinase B
- Placental abruption, 535
- Placental blood flow, 576–577
- Placenta previa, 535
- Plasmin, 379
- Platelets, impact of smoking on, 375–377
- Plausibility, 5–7
- Policy recommendations, 660–664
 advertising, 662, 663, 664
 secondhand smoke exposure, 664–666
- Polonium 210, 41, 227
- Polycyclic aromatic hydrocarbons (PAHs), 11, 37–38
 as biomarkers, 230
 carcinogenicity, 228*t*
 reproductive and developmental effects, 589–599
- Polymorphonuclear leukocytes, 378
- Positive reinforcement, 118–119, 121–122, 124
- Postprandial hypertriglyceridemia, 384–385
- Postprandial lipid changes, 389
- PPROM. *See* Preterm premature rupture of membranes
- Preeclampsia, 534–535, 585–586, 609–610
 mortality and, 534
 2004 Surgeon General's report on, 534, 567, 609
- Pregnancy. *See also* Maternal smoking; Reproductive and developmental effects
 complications, 527–537
 endocrine system, 557
 smoking cessation during, 606–607
 2001 Surgeon General's report on, 557
- Premenopause, 555–557
- Premier cigarettes, 18
- President's Cancer Panel, 648, 652–653, 654
 recommendations, 664–666
- Preterm delivery, 11, 536–537
 placenta previa and, 535
 Surgeon General's reports on, 536
 vitamin deficiencies and, 55
- Preterm premature rupture of membranes (PPROM), 537, 599–600, 610–611
- Prevention, smoking, 606–607
- Primary Malignant Growths of the Lungs and Bronchi, 654
- Progesterone, 587, 608
- Prostacyclin, 380
- Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, 302
- Proteases, 489–494
- Protease-antiprotease imbalance, 495
- Protease inhibitors, 493*t*
- Protein adducts, 54, 245
- Protein kinase A, 226*f*, 291
- Protein kinase B (AKT or PKB), 226, 226*f*, 287, 290–291
- Protein kinase C, 291
- Protein-signaling pathways, lung cancer, 286*f*

P73 gene, 296
P16 gene, 292, 293, 294
 Psychiatric comorbidity, nicotine addiction and, 134–136, 167–169
 P21 protein, 295
 Public Health Service (PHS), 16, 135, 395, 606, 607
 Pulmonary defenses, 440*f*
 Pulmonary disease. *See also* Lungs; *specific diseases*
 conclusions, 11, 496
 future research recommendations, 658
 genetics of, 475–487
 overview of, 437–438
 oxidative stress and, 457–470
 1984 Surgeon General's report on, 440
 2004 Surgeon General's report on, 440
 tissue remodeling, 453–457
 Pulmonary hypertension, 447–449
 Pyrolysis environment, 47

Q

Quest cigarettes, 18
 Quinapril, 374

R

RAD23B gene, 262*t*, 267
 Radioactive elements, 41
 RAS/mitogen-activated protein kinase, 287
 Raven Progressive Matrices Test, 541
 Reactive oxygen species (ROS), 251, 254, 265, 457–459
 Reboxetine, 130
 Recommendations
 policy (*See* Policy recommendations)
 research (*See* Research recommendations)
 Reconstituted tobacco, 45–46
 Red blood cells, 377
 Reduced exposure, methods for, 402–406
 Regulation
 antiapoptotic proteins, 688–690
 smoking cessation during pregnancy, 607–608
 tobacco products, 662–664
 tumor suppressors and proapoptotic proteins, 284–286
 Reinforcement. *See* Nicotine reinforcement
 Relapse
 defined, 170
 lapse-relapse relationship, 171
 natural history of, 170–171
 prevalence, 170–171
 rapidity of, 171
 risk factors (*See* Relapse risk factors)
 Relapse risk factors, 171
 emergent processes, 174–178
 person factors, 172–174
 situational instigators, 178–179
 summary and future directions, 180
 transition from lapse to relapse or recovery, 179–180
 Relative risk (RR), 355
 coronary heart disease, 356*f*
 Report of the Advisory Committee to the U.S. Surgeon General (1964), 7*t*
 Reproductive and developmental effects. *See also* Fertility; Fetal effects; Maternal smoking; Pregnancy
 animal studies, 71–74
 children of smokers, 57–58
 conclusions, 11, 612
 developmental endpoints, 537–554
 endocrine system, 555–561
 evidence summaries, 577–583, 608–611
 immune system, 583–584
 implications, 606
 overview, 523
 placental effect, 566–568
 regulation and policy, 607–608
 reproductive endpoints, 524–527, 601–605
 research recommendations, 658–660
 smoking cessation and prevention, 606–607
 tobacco smoke toxicants and, 584–599
 tubal function, 566
 Research recommendations, 655–660
 cancer, 657
 cardiovascular diseases, 657–658
 nicotine addiction, 655–657
 pulmonary diseases, 658
 reproductive and developmental effects, 658–660
 Respiratory defense mechanisms, 440*f*, 450–451
 adaptive immunity, 450*f*, 452–453, 454*f*
 innate immunity, 450*f*, 451–452, 454*f*
 summary, 456–457
 tissue remodeling, 453–456
 Respiratory disease. *See also* Pulmonary disease; *specific diseases*
 animal studies, 69–71
 conclusions, 11
 nonmalignant, 437–438, 439*t*
 1964 Surgeon General's report on, 437
 2004 Surgeon General's report on, 438*f*
 2006 Surgeon General's report on, 438*t*
 Respiratory system
 defense mechanisms (*See* Respiratory defense mechanisms)
 dosimetry of tobacco smoke in, 439–440
 Retail sales, regulation of, 661, 662–663
 Retinoblastoma protein, 286
 Retinopathy, 386
 Reverse cholesterol transport, 390
 Reward, 118
 Rimonabant, 130
 Risk assessment tools, biomarkers as, 52
 R.J. Reynolds (tobacco manufacturer), 17, 18
 ROS. *See* Reactive oxygen species
 Rosiglitazone, 390
 RR. *See* Relative risk

S

-
- Safe and Drug-Free School Act, 661
 - St. Louis Alpha-1-Antitrypsin Study, 476
 - Saliva biomarkers, 52
 - Salmonella mutagenicity assay, 56, 78
 - SCE. *See* Sister chromatid exchange
 - Schizophrenia, 135–136
 - Secondary reinforcement, 120–121
 - Secondhand smoke exposure, 381
 - cardiovascular disease and, 363
 - conclusions, 9
 - health consequences of, 4*f*, 9
 - low birth weight and, 538
 - during pregnancy, 659
 - recommendations, 664–666
 - Seminal fluid biomarkers, 53
 - Sensitization, 116
 - Sensory-gating deficits, 136
 - Serotonin, 129–130
 - smoking behavior and, 150*f*
 - SERPINA3* gene, 11, 475, 486, 496
 - Sidestream smoke, 31
 - SIDS. *See* Sudden infant death syndrome
 - Signaling cascades, 292
 - Signal transduction, 284–288
 - Sister chromatid exchange (SCE), 58
 - Situational instigators, 171, 178–179
 - Skin-painting studies, 62–63
 - Skool smokeless tobacco products, 115*f*
 - Small airway obstruction, 444, 456
 - Small-cell lung cancer, 292–293
 - Smoke. *See* Tobacco smoke
 - Smokeless tobacco products, 113–114, 115*f*
 - cardiovascular disease and, 366–367, 381
 - maternal use, 539
 - plasma nicotine concentrations, 115*f*
 - Smoking
 - adolescents, 156, 158–160
 - duration, 359
 - epidemiological literature review, 524–555
 - frequency, 119
 - pathophysiological and cellular mechanisms, 555–605
 - reduced, 403–406
 - regulation and policy, 607–608
 - reinforcement *versus* nicotine reinforcement, 120
 - risk reduction, 651–652
 - Smoking behavior
 - African Americans, 48
 - blockage of filter ventilation holes, 16, 49
 - defined, 51
 - heritability of, 10, 137–138
 - molecular genetic research, 138–145
 - phenotypes, 139*t*–140*f*
 - Smoking cessation
 - cardiovascular disease and, 359–360, 390, 394–402
 - conclusions, 408
 - counseling, 396*t*, 398–399, 606–607
 - lipid abnormalities and, 390
 - men, 608
 - mortality and, 360, 394–395
 - pharmacotherapy for, 397*t*–398*t*, 401–402 (*See also* Nicotine replacement therapy; *specific drug*)
 - pregnancy and, 606–607
 - regulation and policy, 607–608
 - 1990 Surgeon General's report on, 395
 - survival curves and, 648
 - Smoking compensation, 16, 18, 111, 119
 - Smoking initiation, 137–138
 - in adolescents (*See* Adolescents)
 - Smoking machine conditions, 60
 - Smoking persistence, 138, 182
 - Smoking prevention, 606–607
 - Smoking recovery, 182. *See also* Relapse
 - Smoking topography, 33, 48
 - Snuff, 114*f*, 115*f*, 357, 366, 586
 - SOD. *See* Superoxide dismutase
 - Sperm, 526–527
 - genetic damage to, 599
 - S-phenylmercapturic acid, 233
 - Spontaneous abortion, 527–531, 532*t*–533*t*, 609
 - Surgeon General's reports on, 530, 531
 - Squamous cell carcinoma, 247, 280*f*
 - Stroke, 361
 - Subfertility, 525–526
 - Sudden death, 361
 - Sudden infant death syndrome (SIDS), 4*f*, 539
 - “Sufficient” causal agents, 8
 - Sulfur-containing gases, 39
 - Superoxide dismutase (SOD), 251, 457
 - 1964 Surgeon General's Report, 5
 - low birth weight, 538
 - respiratory disease, 437
 - 1982 Surgeon General's Report, 5
 - 1984 Surgeon General's Report
 - COPD, 437
 - pulmonary diseases, 440
 - 1988 Surgeon General's Report
 - drug dependence criteria, 106
 - nicotine addiction, 105–106, 180
 - 1990 Surgeon General's Report, 395
 - 2000 Surgeon General's Report, 654
 - 2001 Surgeon General's Report, 524
 - fertility, 526
 - low birth weight, 538
 - menopause, 525
 - perinatal mortality, 539
 - pregnancy, estrogen levels in, 557
 - 2004 Surgeon General's Report
 - birth defects, 539
 - cancer, 225
 - ectopic pregnancy, 531, 609
 - evidence strength, 3, 7
 - low birth weight, 538
 - male fertility, 526

placental abruption, 535
placenta previa, 535
preeclampsia, 534, 567, 609
preterm delivery, 536
preterm premature rupture of membranes, 537
pulmonary diseases, 440
respiratory disease, 438*f*
sudden infant death syndrome, 539
spontaneous abortion, 530, 609
2006 Surgeon General's Report
 cardiovascular disease, 355, 363
 low birth weight, 538
 preterm delivery, 536
 respiratory disease, 438*f*
 spontaneous abortion, 531
Survival curves, 648
Sympathetic nervous system, 123, 367
Synergistic interactions in carcinogenesis, 297–298
Systemic oxidative stress, 469–470

T

Tar delivery, 15, 36, 39
Target populations, 19–20
Tar (particulate) phase of tobacco smoke, 30
Taxes, tobacco, 653, 664–665
T cells, 75–76
Test methods
 FTC, 16
 new products, 19
TGF- α , 600–601
TGF- β 3, 600–601
Thioredoxins, 365
Third National Health and Nutrition Examination Survey, 554
Thrombogenic effects
 blood alterations in, 375–380
 secondhand smoke exposure and, 381
 vascular alterations, 380–381
Thrombosis, 381–382
Thromboxane A/s12/s0, 534
Tissue factor, 380
Tissue plasminogen activator, 380–381
Tissue remodeling, 453–456
Tobacco
 alkaloids, 31–32
 processing, 45–46
 reconstituted, 45–46
 types of, 34, 36
Tobacco casing, 44
Tobacco control measures, 660–666
Tobacco epidemic, global, 647–651, 652–654

Tobacco industry, 15, 20. *See also specific companies*
 marketing, 653–654
 publicly released documents, 16, 33, 34, 116
Tobacco lamina, 9
Tobacco smoke
 activation of cell-surface receptors in airway epithelial cells
 by, 288–292
 additives, effect of, 44–45
 carcinogens in (*See* Carcinogens)
 causation of disease schema, 5*f*
 characteristics, 438–439
 chemistry of (*See* Chemistry of tobacco smoke)
 dosimetry of, 439–440
 gene promoter hypermethylation induction, 292–294
 genotoxicity, 56–59
 inhalation studies, 63–67
 phases, 30–31
 secondhand (*See* Secondhand smoke)
 susceptibility to, 475–487
Tobacco-specific nitrosamines (TSNAs), 35*f*, 79, 226, 232, 252
 as biomarker, 10
 DNA adducts, 10
 lower yield tobacco products, 17
 urinary metabolites, 10
Tolerance, nicotine, 116–117
TP53 gene, 295
 G→T transversions, 279–283
 in lung cancer, 278–279
Transcription-coupled repair, 257–258
Transdermal system. *See* Nicotine patches
Translesion synthesis, 269–272
Treating Tobacco Use and Dependence: Clinical Practice
 Guidelines (PHS), 395
TSNAs. *See* Tobacco-specific nitrosamines
Tubal (oviduct) function, 72, 534, 566, 586
Tumor-suppressor genes, 274–275
 inactivation, 277–278

U

Uncharacterized adducts, 244
Unconditioned stimuli, 120
Unilateral emphysema, 447
United Kingdom Prospective Diabetes Study, 386
University of Minnesota Transdisciplinary Tobacco Use Research
 Center, 19
Upper aerodigestive tract cancer, 58
Uridine-5'-diphosphate-glucuronosyltransferases, 240–241
Urinary biomarkers, 230, 234
U.S. Lung Health Study, 367, 403, 649
U.S. Tobacco Use and Dependence Guideline Panel, 653
Uterine blood flow, 576–577

V

Vapor inhalers, nicotine, 113*t*
Varenicline, 154, 401, 402
Vascular homeostasis, 371–372
Vasoconstriction, coronary, 369
Vasodilation, endothelium-dependent, 372–373
Vigabatrin, 128
Virchow's triad, 375
Vitamin C, 381, 461
 deficiency, 599, 611
Vitamin E, 461
Volatile compounds, 38–40
Volatile nitrosamines, 34
Von Willebrand protein, 380

W

Waterpipe smoking, 655
Wechsler Preschool and Primary Scale of Intelligence - Revised, 541
Weight. *See also* Low birth weight
 smoking and, 77, 129
WHO. *See* World Health Organization
Withdrawal, 117–118. *See also* Relapse
 animal studies, 131
 behavioral signs, 132–133
 molecular mechanisms, 133–134
 neurochemical correlates, 132
 neurosubstrates of, 131–133
 psychiatric comorbidity, 134–136
 receptors, 132–133
 symptoms, 175–176
Women. *See also* Reproductive and developmental effects
 cardiovascular disease, 360
 endocrine system, 555–557, 558*t*–560*t*
 mortality, 360
 smoking behavior, 48
 smoking topography, 33
 2001 Surgeon General's report on, 524
 withdrawal, 118
World Health Organization (WHO)
 on global tobacco epidemic, 647
 MPOWER Framework, 653–654
 research, 386

X

Xeroderma pigmentosum A (XPA), 266
Xeroderma pigmentosum C (XPC), 266
Xeroderma pigmentosum complementation group D (XPD), 266–267
XPF/ERCC1 gene complex, 267
XPG/ERCC5 gene complex, 267
XRCC1 (cross-complementation group 1 for excision repair) gene, 264–265, 266

Y

Youth. *See also* Adolescents
 marketing to, 19

Z

Zinc
 deficiencies of, 599–600
 in tobacco smoke, 390, 613
Zuckerman Sensation Seeking Scale, 159